The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.
Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.
The FTC staff had focused on hemophilia treatments since Roche markets Hemlibra, the report said.
Following the staff’s recommendation, officials at the top of the FTC’s Bureau of Competition must weigh in. The next step would be a vote by the FTC chairman and four commissioners.
The deal must also win approval from the UK’s Competition and Markets Authority, which said this week that it had a deadline of mid-December for a Phase 1 decision. A Phase 2 probe would be more in-depth and detailed.
Roche, Spark and the FTC all declined comment.
By Diane Bartz
Source: Reuters
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.